More and more biologics and small molecules enter the therapeutic arena in psoriasis, making the choice of the right drug increasingly complex. In this talk, Prof. Mark Lebwohl (Icahn School of Medicine at Mount Sinai, USA) addressed therapy for paediatric patients and for women with severe psoriasis who wish to become pregnant .
For women who wish to become pregnant, it is important to find an agent that does not cross the placenta. One such agent is the TNFα blocker certolizumab pegol . The CRIB trial showed that there is only minimal to no placental transfer from mother to infant; only 1 infant from 14 exposed mothers had a minimal certolizumab pegol level of 0.042 µg/ml .
TNFα blockers seem to be relatively safe during pregnancy. A cohort study analysing the outcomes after anti-rheumatic drug use before and during pregnancy among 150,000 pregnant women and expecting fathers f...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Biologic psoriasis treatment to lower cardiovascular risk? Next Article
How to manage cutaneous side effects of immunotherapy »
Table of Contents: AAD 2020
Psoriasis – What Is Hot?
Systemic Therapies for Dermatologists
Hidradenitis Suppurativa/Acne Inversa
Pearls of the Posters
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.